Management and Burden of Hidradenitis Suppurativa: An Italian Hybrid Real-World Study.

IF 4.2 3区医学 Q1 DERMATOLOGY

Dermatology and Therapy Pub Date : 2025-07-01 Epub Date: 2025-05-09 DOI:10.1007/s13555-025-01407-0

Anna Balato, Marina Venturini, Massimiliano Scalvenzi, Caterina Foti, Giovanni Maifredi, Simona Serao Creazzola, Stefania Antonacci, Arianna Tonelli, Diletta Valsecchi, Donatella Vassellatti, Riccardo Cipelli, Alessandra Ori, Lucia Casoli

{"title":"Management and Burden of Hidradenitis Suppurativa: An Italian Hybrid Real-World Study.","authors":"Anna Balato, Marina Venturini, Massimiliano Scalvenzi, Caterina Foti, Giovanni Maifredi, Simona Serao Creazzola, Stefania Antonacci, Arianna Tonelli, Diletta Valsecchi, Donatella Vassellatti, Riccardo Cipelli, Alessandra Ori, Lucia Casoli","doi":"10.1007/s13555-025-01407-0","DOIUrl":null,"url":null,"abstract":"Introduction: Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease that severely impacts quality of life and carries a substantial economic burden.Methods: This multicenter observational study generated real-world evidence on HS in Italy, focusing on clinical profiles, management, and costs. Data were collected from 50 adults at four specialized centers, combining primary data with retrospective administrative data.Results: Patients with moderate-to-severe disease had longer diagnostic delays (median 1.8 versus 0.7 years), lower symptom control (40.7% versus 95.2%), and worse quality of life (Dermatology Life Quality Index: 11.8 versus 8.0) than those with mild disease. Furthermore, HS was associated with higher costs in moderate-to-severe cases, including greater direct (€2214 versus €873) and indirect expenses (€2435 versus €262).Conclusions: The findings highlight the social and economic burden of HS and emphasize the need for increased healthcare awareness for earlier diagnosis and better management.","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"1771-1785"},"PeriodicalIF":4.2000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12126415/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13555-025-01407-0","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/9 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease that severely impacts quality of life and carries a substantial economic burden.

Methods: This multicenter observational study generated real-world evidence on HS in Italy, focusing on clinical profiles, management, and costs. Data were collected from 50 adults at four specialized centers, combining primary data with retrospective administrative data.

Results: Patients with moderate-to-severe disease had longer diagnostic delays (median 1.8 versus 0.7 years), lower symptom control (40.7% versus 95.2%), and worse quality of life (Dermatology Life Quality Index: 11.8 versus 8.0) than those with mild disease. Furthermore, HS was associated with higher costs in moderate-to-severe cases, including greater direct (€2214 versus €873) and indirect expenses (€2435 versus €262).

Conclusions: The findings highlight the social and economic burden of HS and emphasize the need for increased healthcare awareness for earlier diagnosis and better management.

查看原文本刊更多论文

化脓性汗腺炎的管理和负担：一项意大利混合现实世界研究。

化脓性汗腺炎（HS）是一种慢性炎症性皮肤病，严重影响生活质量并带来巨大的经济负担。方法：这项多中心观察性研究收集了意大利HS的真实证据，重点关注临床概况、管理和成本。数据收集自4个专业中心的50名成年人，将原始数据与回顾性管理数据相结合。结果：与轻度疾病患者相比，中重度疾病患者的诊断延迟时间更长（中位1.8年对0.7年），症状控制较低（40.7%对95.2%），生活质量较差（皮肤病生活质量指数：11.8对8.0）。此外，HS与中重度病例的更高成本相关，包括更高的直接费用（2214欧元对873欧元）和间接费用（2435欧元对262欧元）。结论：研究结果突出了HS的社会和经济负担，并强调需要提高卫生保健意识，以便早期诊断和更好地管理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Dermatology and Therapy Medicine-Dermatology

CiteScore

6.00

自引率

8.80%

发文量

187

审稿时长

6 weeks

期刊介绍： Dermatology and Therapy is an international, open access, peer-reviewed, rapid publication journal (peer review in 2 weeks, published 3–4 weeks from acceptance). The journal is dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of dermatological therapies. Studies relating to diagnosis, pharmacoeconomics, public health and epidemiology, quality of life, and patient care, management, and education are also encouraged. Areas of focus include, but are not limited to all clinical aspects of dermatology, such as skin pharmacology; skin development and aging; prevention, diagnosis, and management of skin disorders and melanomas; research into dermal structures and pathology; and all areas of aesthetic dermatology, including skin maintenance, dermatological surgery, and lasers. The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/case series, trial protocols, and short communications. Dermatology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an International and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals. The journal appeals to a global audience and receives submissions from all over the world.